AICDA and Hodgkins lymphoma: In literature, there is to date no evidence-based mention about a possible link existing between leniolisib employment and Hodgkin’s lymphoma but only a pure inductive hypothesis regarding the potential oncogenic role of PI3Kδ inhibitor-related AID over-expression; rather, leniolisib-related significant regression of lymphadenopathies and splenomegaly could reduce the risk for neoplastic degeneration.